FindTrial
Sign In

Monitoring of DC and T cell functions in healthy controls and patients with prostate cancer treated with GM-CSF transduced allogeneic vaccines and anti-CTLA-4

Monitoring of DC and T cell functions in healthy controls and patients with prostate cancer treated with GM-CSF transduced allogeneic vaccines and anti-CTLA-4 - Frequency and functionality of immune cells in healthy controls

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34152
Enrollment
12
Registered
2011-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

onderzoek van immuuncellen van gezonde mensen not applicable

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy men without a history of cancer or auto-immune diseases age 65-75 years

Exclusion criteria

Exclusion criteria: Cancer patients Patients with auto-immune diseases women

Design outcomes

Primary

MeasureTime frame
FACS analysis the following markers will be measured on dendritic cells and T cells: a) peripheral blood dendritic cells and monocytes: 1) CD1c high/CD14neg/BDCA1+ cells (cDC1) 2) CD1c high/CD14neg/BDCA3+ cells (cDC2) 3) CD1c high/CD14low/MDC-8+ cells (cDC3) 4) CD1c neg/CD14neg/BDCA2+ cells (plasmacytoid cells (pDC)) en 5) CD11c+/CD14+ monocytes. b) peripheral blood CD4+ en CD8+ T cells (CD3, CD4, CD8, CD45RA, CD45RO, CD27, CD25, and HLA-DR, CTLA-4, PD-1) en regulatory T cells (CD4+/CD25high/FoxP3+)—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)